PGEN (Precigen) ROCE % : -189.55% (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Precigen ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Precigen's annualized ROCE % for the quarter that ended in Mar. 2025 was -189.55%.

Precigen ROCE % Historical Data

The historical data trend for Precigen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen ROCE % Chart

Precigen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-28.24

-30.86

-31.65

-72.27

-101.68

Precigen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-81.20	-309.73	-170.57	-85.22	-189.55

Precigen ROCE % Calculation

Precigen's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-128.022	/	( ( (151.043 - 22.985)	+	(145.266 - 21.518) )	/ 2 )
	=	-128.022	/	( (128.058	+	123.748)	/ 2 )
	=	-128.022	/	125.903
	=	-101.68 %

Precigen's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-216.608	/	( ( (145.266 - 21.518)	+	(128.787 - 23.986) )	/ 2 )
	=	-216.608	/	( ( 123.748	+	104.801 )	/ 2 )
	=	-216.608	/	114.2745
	=	-189.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Precigen (NAS:PGEN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Precigen ROCE % Related Terms

Thank you for viewing the detailed overview of Precigen's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Precigen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

I5X:Germany I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Executives

Randal J Kirk	director, 10 percent owner, officer: Chief Executive Officer	1881 GROVE AVENUE, RADFORD VA 24141
Jeffrey Thomas Perez	officer: SVP, IP Affairs	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari	director, officer: President and CEO	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah	officer: Chief Operating Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian	officer: Chief Financial Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Donald P. Lehr	officer: Chief Legal Officer	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro	director	155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez	director	C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley	director	9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a.	10 percent owner	ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170